Meeting the Challenge of Metastatic Cancer
Traditional cancer therapy has relied on a strictly cytotoxic approach that views non-metastatic and metastatic tumor cells as identical in terms of molecular biology and sensitivity to therapeutic intervention. Mounting evidence suggests that, in fact, non-metastatic and metastatic tumor cells differ in key characteristics that could explain the capacity of the metastatic cells to not only escape the primary organ but also to survive while in the circulation and to colonize a distant organ. This therapeutic approach contributes to the notably poor outcomes in patients diagnosed with metastatic disease and represents a clear, unmet clinical need.
TransCode is developing a targeted therapeutic treatment of metastatic cancer that leads to complete regression and lifetime remission after just 4-6 weeks of treatments.
This radically novel and highly promising therapeutic strategy against cancer relies on specific eradication of metastatic tumor cells – cells that have acquired the ability to escape into the circulation, survive during transit, and colonize a distant vital organ, such as the lungs and brain. As shown by the scientific founders, this therapeutic approach spares healthy organs and has essentially no systemic toxicity compared to chemotherapy.
Metastatic cells are uniquely capable of leaving the primary tumor, surviving in the circulation and colonizing a distant organ
Click image to enlarge
A Bold Focus on Metastasis
Metastasis is when cancer spreads to a different part of the body from where it originated. Metastatic cells are uniquely capable of leaving the primary tumor, surviving in the circulation and colonizing a distant organ. TransCode’s therapeutic strategy is focused on the specific eradication of metastatic tumor cells through a biological phenomenon that the co-founders have termed “metastamiR™ dependence”. MetastamiR™ dependence is defined as the inability of metastatic tumor cells to survive without the overexpression of a specific regulatory molecule, microRNA-10b, a molecule essential for sustaining metastatic cell viability.
Without the high level of expression of microRNA-10b, these cells, stripped out of their natural microenvironment, do not have the adaptive mechanism they need in order to survive.
TransCode Therapeutics, Inc. is a Boston based pre-clinical biopharmaceutical company focused on discovery, development and commercialization of a pipeline of innovative microRNA-targeted therapeutics for treating metastatic cancer.